Evidence map›Paper›PMID 39957803›Full record

ArticleFrontiers in oncology2024

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Toshio ShimizuDepartment of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
John PowderlyCarolina BioOncology Institute, Huntersville, NC, United States.
Albiruni Abdul RazakCancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada.
Patricia LoRussoYale Cancer Center, Yale University, New Haven, CT, United States.
Kathy D MillerDepartment of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Steven KaoDepartment of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Sarah KongpachithAbbVie Bay Area, South San Francisco, CA, United States.
Catherine TribouleyAbbVie Bay Area, South San Francisco, CA, United States.
Michelle GrahamAbbVie Bay Area, South San Francisco, CA, United States.
Brian StollAbbVie Bay Area, South San Francisco, CA, United States.
Maulik PatelAbbVie Bay Area, South San Francisco, CA, United States.
Mohammad SahtoutAbbVie Bay Area, South San Francisco, CA, United States.
Martha BlaneyAbbVie Bay Area, South San Francisco, CA, United States.
Rachel LeibmanAbbVie Bay Area, South San Francisco, CA, United States.
Talia GolanInstitute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Anthony TolcherNew Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2024.1376551.].

Indexed as

advanced solid tumorsanti-PD-1 antibodycombination drug therapyGARPimmunotherapyinvestigational therapiesTGF-ß1tumor microenvironment (TME)

Identifiers

PMID39957803
PMCPMC11826311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.